Loading search results
Sponsor study identifier
interventional
400
1 country
1
Study Start
November 30, 2021
Actual (reported)Primary Completion
June 30, 2022
Actual (reported)Study Completion
November 30, 2022
Actual (reported)Clinical pharmacy services aim to enhance patient outcomes and reduce the risk of potential drug-related harm by offering patient-centred pharmaceutical care. In the hospital setting, clinical pharmacists collaborate with physicians as part of a multidisciplinary team to identify and prevent DRPs (Drug-related problems). Clinical pharmacist interventions encompass 'any action initiated by a pharmacist that directly results in patient management or a modification in medication.' The favourable clinical and economic impacts of interventions have been well-established for decades. Clinical pharmacists have played an important role in ensuring the effective and correct use of medicines in many settings. This study aims to investigate the clinical pharmacy services provided by clinical pharmacists to patients receiving antithrombotic therapy. For this study, patients were divided into two groups: a control group and an intervention group. A comprehensive medication review will be conducted by the clinical pharmacist for both the control and intervention groups. Drug-related problems such as drug selection, dose errors, possible drug-drug interactions, and inappropriate drug use, will be identified. In the control group, no interventions will be made by the clinical pharmacist. In the intervention group, solution recommendations for identified and clinically significant issues will be presented to the physician, and the provided services will be documented. Furthermore, the groups will be evaluated for whether there are any hospital readmissions within 1 and 3 months following discharge for the patients.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
November 30, 2022
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
November 30, 2021
Actual (reported)June 30, 2022
Actual (reported)November 30, 2022
Actual (reported)December 5, 2023
Actual (reported)January 5, 2024
Actual (reported)Acceptance rate of suggested intervention (number)
Acceptance rate of suggested intervention. Medication-related problems and recommendations are classified according to PCNE (Pharmaceutical Care Network Europe) version 9.1. It was recorded how many suggestions were made in the intervention group and how many of these suggestions were accepted.
From the date of randomization until there are 200 patient participants in each group. Average 1 year.
Length of hospital stay (days)
Length of hospital stay
From date of randomization until the date of discharge from the hospital, assessed up to 1 year.
Within three months readmission (number of patients re-admitted to hospital)
In order to determine which group of patients has the highest number of hospital re-admissions and to evaluate whether there is a significant difference between the groups.
Whether patients were readmitted to the hospital within three months of discharge or transfer.
For patients in this group, no intervention (i.e. recommendation) will be made to physicians by the clinical pharmacist. Within the intervention group, patient characteristics such as the length of hospital stay, reason for hospitalization, underlying conditions, and the appropriateness of prescribed medications were evaluated for the patients who received antithrombotic treatment and met the inclusion criteria. The participant will take standard treatment. Evaluations will be recorded. Follow-up was performed to determine whether the patients had a re-admission within 3 months.
For patients in this group, intervention (i.e. recommendation) will be made to physicians by the clinical pharmacist. Within the intervention group, patient characteristics such as the length of hospital stay, reason for hospitalization, underlying conditions, and the appropriateness of prescribed medications were evaluated for the patients who received antithrombotic treatment and met the inclusion criteria. Through medication reviews, evaluations were made to identify drug-related problems and provide solutions to these problems. The clinical pharmacist provided recommendations to the physicians regarding significant clinically important problems. Additionally, follow-up was performed to determine whether the patients had a re-admission within 3 months.
The drugs administered to patients within 24-48 hours after hospitalization were recorded. A detailed medication review will be conducted by the clinical pharmacist during the participants' hospitalization.As a result of a comprehensive evaluation, recommendations were made to doctors regarding drug-related problems and were recorded.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Bezmialem Vakıf Üniversitesi
Istanbul, Fatih, 34096, Turkey (Türkiye)
Fikret Vehbi Izzettin, Prof.Dr.
Bezmialem Vakıf Üniversitesi
400 participants (actual enrollment reported by the registry).
First Submitted
December 5, 2023
First Posted
January 5, 2024
Study Start
November 30, 2021
Actual (reported)Contact the study team to confirm eligibility.
Primary Completion
June 30, 2022
Actual (reported)Study Completion
November 30, 2022
Actual (reported)Last Updated
January 5, 2024
Record last verified: 2024-01
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: